Background
Actinomadura geliboluensis
was first isolated in 2012 in Gelibolu, Canakkale, Turkey, and has not been reported to be isolated from humans until now. We have isolated it from the bronchoalveolar lavage fluid (BLF) of a patient with pneumonia and found its drug resistance. It is the first time that
Actinomadura geliboluensis
has been isolated from humans since its discovery and naming. This case may provide new ideas and methods for the clinical diagnosis and treatment of pulmonary actinomycosis.
Case Description
The patient was a 75-year-old male who was hospitalized in a township hospital and failed to improve after penicillin treatment. After admission to our hospital, the patient was treated with piperacillin/tazobactam according to clinical guidelines for 14 days.
Actinomadura geliboluensis
was isolated from the patient’s BLF and was identified by 16S rRNA sequencing. This report shows the biological characteristics and in vitro drug susceptibility testing, as well as the genomics analysis based on next-generation sequencing (NGS). The results demonstrated that
Actinomadura geliboluensis
was easy to be mistakenly identified as
Actinomyces
dental caries by using the Merieux ANC identification card. Based on the MIC test,
Actinomadura geliboluensis
was susceptible to tetracyclines, quinolones and sulfonamides, but resistant to carbapenems, penicillins and cephalosporins. The K-B test results showed
Actinomadura geliboluensis
was highly sensitive to piperacillin/tazobactam. Genomic analysis based on NGS showed that the
Actinomadura geliboluensis
belongs to
Planobispora rosea
EF-Tu mutants conferring resistance to inhibitor
GE2270A, AAC(3)-VIIa, vanRO, chrB
, and
mexY
.
Conclusion
Actinomycetes
is generally sensitive to Penicillin but
Actinomadura geliboluensis
is not. In vitro drug susceptibility test is needed to support individualized drug use to avoid delay in the disease.